Unknown PHASE2 INTERVENTIONAL 1-arm NCT04363255

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Efficacy and Safety of First-line Etoposide/Platinum-based Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in Extensive Small Cell Lung Cancer: A Single-arm, Multicentral Phase II Study

Sponsor: Taizhou Hospital

Conditions Small Cell Lung Carcinoma

Interventions Anlotinib hydrochloride Carboplatin Injection Cisplatin injection Etoposide Injection Toripalimab

Updated 5 times since 2020 Last updated: Apr 26, 2020 Started: May 1, 2020 Primary completion: Dec 31, 2022 Completion: Mar 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Small Cell Lung Carcinoma, this trial is ongoing. The trial is conducted by Taizhou Hospital and has accumulated 5 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
May 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — May 2023 [monthly]

Not Yet Recruiting PHASE2
May 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Taizhou Hospital

Data source: Taizhou Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taizhou, China